Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

Psoriasis

Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C

Br J Dermatol.

Siegel S, Winthrop K, Ehst B, Ortega Loayza A

doi: 10.1111/bjd.17444.

AcnePsoriasis

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Br J Dermatol

Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB

doi: 10.1111/bjd.20413

Psoriasis

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1111/bjd.18981.

Melanoma and Skin CancerPsoriasis

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries

J Eur Acad Dermatol Venereol.

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC

doi: 10.1111/jdv.15203.

COMMENTED

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C

doi: 10.1016/S0140-6736(19)30952-3.

Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA Dermatol.

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ

doi: 10.1001/jamadermatol.

Psoriatic Arthritis

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Ann Rheum Dis.

Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P

doi: 10.1136/annrheumdis-2020-217372.

Psoriasis

Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study

J Invest Dermatol.

Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CE, Reynolds N, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group and PSORT consortium

doi: 10.1016/j.jid.2018.07.028.

Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies

Hum Vaccin Immunother.

Restivo V, Costantino C, Bono S, Maniglia M, Marchese V, Ventura G, Casuccio A, Tramuto F, Vitale F

doi: 10.1080/

Related content

Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study

Influenza vaccine effectiveness among high-risk groups: a systematic literature review and meta-analysis of case-control and cohort studies